Do drugmakers need a reality check on prices?

02/11/2013 | Xconomy

Drugmakers have come under fire lately for six-figure annual pricing on some new drugs, and payers are beginning to push back. Instead of developing drugs for rare diseases as a way to stabilize profits, drugmakers should improve diagnostics and precision treatments, and should develop better treatments for diabetes, depression and other chronic diseases, says Alkermes CEO Richard Pops.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN